On May 31, 2021, DayTwo, a leading Israeli precision medicine company, announced that it closed a $37 million financing round to “continue development of technologies and solutions designed to improve the health of people with diabetes and other metabolic diseases.”

A Naschitz Brandes Amir team including partners Noga Devecseri Spira and Assif Rosenberg and associate Noa Nitzan represented DayTwo in the recent transaction.

For more information, please see a Globes article covering the fundraise.